BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).

被引：6
|
作者：
El-Rayes, Bassel F.
Richards, Donald A.
Cohn, Allen Lee
Richey, Stephen Lane
Feinstein, Trevor
Kundranda, Madappa N.
El-Khoueiry, Anthony B.
Melear, Jason M.
Braiteh, Fadi S.
Hitron, Matthew
Ortuzar, Waldo Feliu
Khan, Waheed
Xu, Bo
Li, Wei
Li, Youzhi
Li, C. J.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Texas Oncol, Tyler, TX USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] US Oncol Network, McKesson Specialty Hlth, Texas Oncol, Ft Worth, TX USA
[5] Piedmont Canc Inst, Fayetteville, GA USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[8] Texas Oncol, Round Rock, TX USA
[9] US Oncol Network, McKesson Specialty Hlth, The Woodlands, TX USA
[10] Boston Biomed Inc, Cambridge, MA USA
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Boston Biomed Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：5
相关论文
共 44 条
  • [41] A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS']JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC).
    Shi, Ying-Hong
    Ji, Yuan
    Liu, Wei-Ren
    Pang, Yan-Rui
    Ding, Zhen-Bin
    Fu, Xiu-Tao
    Zhang, Xin
    Huang, Cheng
    Sun, Yun-Fan
    Zhu, Xiao-Dong
    Sun, Hui-Chuan
    Zhou, Jian
    Fan, Jia
    CANCER RESEARCH, 2021, 81 (13)
  • [42] TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC)
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Ikeda, Masafumi
    Torimura, Takuji
    Aikata, Hiroshi
    Izumi, Namiki
    Yamasaki, Takahiro
    Hino, Keisuke
    Kuzuya, Teiji
    Isoda, Norio
    Yasui, Kohichiroh
    Aino, Hajime
    Ido, Akio
    Kawabe, Naoto
    Nakao, Kazuhiko
    Wada, Yoshiyuki
    Yoshimura, Kenichi
    Okusaka, Takuji
    Furuse, Junji
    Arai, Yasuaki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] A phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC).
    Faivre, S. J.
    Fartoux, L.
    Bouattour, M.
    Bumsel, F.
    Dreyer, C.
    Raymond, E.
    Rosmorduc, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [44] PHASE I SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF AVE1642, A HUMAN MONOCLONAL ANTIBODY INHIBITING THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R/CD221), ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH SORAFENIB AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Faivre, Sandrine
    Fartoux, Laetitia
    Bumsel, Franck
    Bouattour, Mohamed
    Dreyer, Chantal
    Raymond, Eric
    Rosmorduc, Olivier
    HEPATOLOGY, 2010, 52 (04) : 466A - 466A
12345